Navigation Links
Agendia Signs Contract with Blue Shield of California
Date:1/5/2012

IRVINE, Calif. and AMSTERDAM, Jan. 5, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that the company has signed a contract with Blue Shield of California, making Agendia an in-network provider. The move paves the way for future in-network coverage for MammaPrint® and other Agendia tests by Blue Cross affiliates across the United States. Developed and commercialized by Agendia, MammaPrint is the keystone of the company's Symphony™ suite of breast cancer assays, and the first and only molecular breast cancer recurrence assay cleared by the U.S. Food and Drug Administration (FDA) in February 2007. The gene expression signature assay is used by physicians as a prognostic and predictive tool to identify patients whose risk of metastases is high, requiring chemotherapy, and those at a low risk of metastases, who can be treated just as effectively with other therapies that cause fewer adverse side effects.

"Agendia's contract with Blue Shield of California not only provides more patients with access to MammaPrint, but it also has the potential to open the door to future coverage across the Blue Shield network," said Agendia's CEO, David Macdonald.

As a result of the contract, Agendia will be reimbursed for its MammaPrint test at an in-network rate, benefiting patients by reducing any financial obligation they might carry. Several major payers, including Medicare, Humana, United and others have issued medical coverage policies for MammaPrint. In addition to Blue Shield of California, Agendia has entered contracts with Palmetto, Humana, Coventry and several national PPO plans.

About Agendia:
Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. A
'/>"/>

SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
2. EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
3. Agendia Successfully Completes Bi-Annual FDA Inspection
4. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
5. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
6. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
7. Agendia Raises US $23 Million in Series E Financing
8. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
9. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
10. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
11. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Amici Procurement Migrates to the ... Procurement has chosen Microsoft Cloud Solution Provider iomart ... 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... in the bio-tech sector with a unique procurement service, ... to help them obtain best value. Its IT platform ...
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... 1, 2015 InferMed , ... will ... evidence-based clinical s olutions suite   ... information products and services, announced today the acquisition of  InferMed ... (CDS) technology company. InferMed,s Arezzo technology supports clinicians ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... , , ... ... ... , , ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:YM sees nimotuzumab license unaffected by civil claim against licensor 2YM sees nimotuzumab license unaffected by civil claim against licensor 3YM sees nimotuzumab license unaffected by civil claim against licensor 4YM sees nimotuzumab license unaffected by civil claim against licensor 5Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 2Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 3Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 4Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 5Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 6Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 2Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 3Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 4Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 5Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 6Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 7Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 8Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 9Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 10Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 11
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces that its ... segment on "Money on the Mark", scheduled to air on ... June 20 th . The broadcast ... from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... cell organisms with no nervous system or brain. So ... a complex community called a biofilm "decide" between different ... that forms the biofilm)? In the prestigious ... Microbiology,s meeting in Harrogate, (Monday 30 March) Dr Nicola ...
... cancer gene - one that is common to many cancers and ... - a gene on the X chromosome called UTX - is ... esophageal cancers. UTX plays a role in overall regulation of ... genes with similar roles will also be found to be involved ...
... Nature , researchers at Brandeis University and the MRC Laboratory ... light on a crucial step in the complex process by ... human cell and frequently at which point genetic disease develops ... able to crystallize a very large complex of a macromolecular ...
Cached Biology News:Getting down to cancer basics 2Getting down to cancer basics 3A splice of life 2